Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Retina. 2021 Jan 1;41(1):208–212. doi: 10.1097/IAE.0000000000002782

Table 1.

Patient and disease characteristics by treatment dosing.

Characteristics 25 ug n (%) 30 ug n (%)
Number of injections 110 364
Number of eyes a 49 106
Eye
  OD 54 (49.1) 168 (46.2)
  OS 56 (50.9) 196 (53.8)
Age at injection (years)
  Median (range) 3 (1, 16) 3 (0, 18)
Weight (kg) at baseline
  Median (range) 15 (5, 62) 14 (7, 63)
Reese-Ellsworth Stage
  Unknown 0 231
  2A 2 (1.8) 2 (1.5)
  2B 2 (1.8) 1 (0.8)
  3A 3 (2.7) 13 (9.8)
  3B 7 (6.4) 5 (3.8)
  4A 6 (5.5) 8 (6.0)
  4B 5 (4.5) 2 (1.5)
  5A 20 (18.2) 7 (5.3)
  5B 65 (59.1) 95 (71.4)
International Classification of Retinoblastoma (ICRB)
  Unknown 0 231
  1 0 (0.0) 1 (0.8)
  2 1 (0.9) 7 (5.3)
  3 17 (15.5) 4 (3.0)
  4 74 (67.3) 99 (74.4)
  5 18 (16.4) 22 (16.5)
Time between injections
  Unknown 0 6
  No prior injections 0 (0.0) 1 (0.4)
  <=1 week 0 (0.0) 114 (44.4)
  1–2 weeks 0 (0.0) 19 (7.4)
  2–4 weeks 36 (45.6) 37 (14.4)
  4+ weeks 43 (54.4) 86 (33.5)
Iris color
  Blue 16 (14.5) 65 (17.9)
  Light brown 5 (4.5) 96 (26.4)
  Dark brown 89 (80.9) 203 (55.8)
Seed type
  Non-vitreous 56 (50.9) 90 (24.7)
  Vitreous 54 (49.1) 274 (75.3)
Formulation
  No alcohol 110 (100.0) 109 (29.9)
  With alcohol 0 (0.0) 255 (70.1)
Concomitant OAC
  No 99 (90.0) 294 (80.8)
  Yes 11 (10.0) 70 (19.2)
Concomitant Topotecan
  No 105 (95.5) 312 (85.7)
  Yes 5 (4.5) 52 (14.3)
Concomitant focal treatment
  No 28 (25.5) 234 (64.3)
  Yes 82 (74.5) 130 (35.7)
New injection clock hour b
  Unknown 8 19
  No 82 (80.4) 250 (72.5)
  Yes 20 (19.6) 95 (27.5)
a

The same eye could have received 25ug and 30ug injections. Therefore, the sum of the number of eyes from the two columns does not equal the number of eyes in the dataset.

b

New injection clock site hour was set to “No” for the 1st injection